Privia Health Group, Inc. (PRVA)
NASDAQ: PRVA · Real-Time Price · USD
22.80
-0.21 (-0.93%)
At close: Jun 5, 2025, 4:00 PM
22.80
0.00 (0.02%)
After-hours: Jun 5, 2025, 4:00 PM EDT
Privia Health Group Stock Forecast
Stock Price Forecast
According to 14 professional analysts, the 12-month price target for Privia Health Group stock ranges from a low of $20 to a high of $40. The average analyst price target of $27.93 forecasts a 22.53% increase in the stock price over the next year.
Price Target: $27.93 (+22.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Privia Health Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 6 | 6 | 6 | 5 | 4 |
Buy | 7 | 8 | 10 | 9 | 9 | 9 |
Hold | 2 | 2 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 16 | 17 | 16 | 15 | 14 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Buy Maintains $29 → $32 | Buy | Maintains | $29 → $32 | +40.38% | May 28, 2025 |
Barclays | Barclays | Hold Maintains $23 → $24 | Hold | Maintains | $23 → $24 | +5.29% | May 27, 2025 |
JMP Securities | JMP Securities | Buy Reiterates $29 | Buy | Reiterates | $29 | +27.22% | Apr 28, 2025 |
Baird | Baird | Buy Maintains $24 → $26 | Buy | Maintains | $24 → $26 | +14.06% | Apr 15, 2025 |
Barclays | Barclays | Hold Maintains $21 → $23 | Hold | Maintains | $21 → $23 | +0.90% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
3.31B
from 1.74B
Increased by 90.63%
Revenue Next Year
3.66B
from 3.31B
Increased by 10.51%
EPS This Year
0.21
from 0.11
Increased by 92.08%
EPS Next Year
0.42
from 0.21
Increased by 101.06%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.5B | 4.0B | 4.6B | ||
Avg | 3.3B | 3.7B | 4.1B | ||
Low | 3.2B | 3.4B | 3.7B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 98.9% | 20.1% | 26.0% | ||
Avg | 90.6% | 10.5% | 12.7% | ||
Low | 81.4% | 3.4% | 1.7% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.30 | 1.16 | 0.58 |
Avg | 0.21 | 0.42 | 0.46 |
Low | 0.12 | 0.25 | 0.39 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 176.8% | 446.7% | 35.9% |
Avg | 92.1% | 101.1% | 9.3% |
Low | 6.9% | 16.0% | -7.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.